Targeted Protein Degradation

Development of small molecules, often bifunctional (e.g., PROTACs) or molecular glues, that induce the ubiquitin-proteasome system or autophagy to selectively degrade specific disease-causing proteins.

18,844 US filings from 5,422 companies since 2023 · 2023: 5,156 · 2024: 5,922 · 2025: 5,505 · 2026 YTD: 2,261

Heterocyclic Compounds (Pharma)

Top companies

Ranked by filings in this theme since 2023. 2026 is partial.

#	Company	Since 2023	2023	2024	2025	2026 YTD	YoY
1	The Regents of the University of California	291	89	102	69	31	-32.4%
2	Dana-Farber Cancer Institute, Inc.	214	60	61	63	30	+3.3%
3	Hoffmann-La Roche Inc.	165	49	44	47	25	+6.8%
4	Novartis AG	147	39	48	37	23	-22.9%
5	Genentech, Inc.	146	49	37	46	14	+24.3%
6	Regeneron Pharmaceuticals, Inc.	138	34	40	50	14	+25.0%
7	UNIVERSITY OF MASSACHUSETTS	134	31	36	44	23	+22.2%
8	Incyte Corporation	132	25	49	39	19	-20.4%
9	Ionis Pharmaceuticals, Inc.	130	35	41	40	14	-2.4%
10	Dyne Therapeutics, Inc.	119	34	41	40	4	-2.4%
11	Kymera Therapeutics, Inc.	119	44	23	32	20	+39.1%
12	THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA	115	38	40	23	14	-42.5%
13	The Board of Trustees of the Leland Stanford Junior University	113	33	40	29	11	-27.5%
14	Merck Sharp & Dohme LLC	109	31	39	24	15	-38.5%
15	President and Fellows of Harvard College	109	33	35	23	18	-34.3%
16	Yale University	105	29	38	32	6	-15.8%
17	The Broad Institute, Inc.	100	21	29	39	11	+34.5%
18	Revolution Medicines, Inc.	99	21	25	40	13	+60.0%
19	ARVINAS OPERATIONS, INC.	98	13	38	31	16	-18.4%
20	AMGEN INC.	96	16	23	40	17	+73.9%
21	The Johns Hopkins University	95	28	29	26	12	-10.3%
22	Board of Regents, The University of Texas System	93	34	25	27	7	+8.0%
23	Wyvern Pharmaceuticals Inc.	92	·	3	59	30	+1866.7%
24	The General Hospital Corporation	89	32	27	20	10	-25.9%
25	Bristol-Myers Squibb Company	84	24	29	25	6	-13.8%